On Sept. 25, 2025, Glaukos, an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, celebrated the groundbreaking of its new state-of-the-art research, development, and manufacturing facility in Huntsville, Alabama.

The new site represents a major milestone in the company’s commitment to strengthening U.S. manufacturing, creating high-quality jobs, and driving the next generation of innovation in American healthcare.

The agreement includes the development of a new 200,000 square-foot R&D and manufacturing facility to be built on 25 acres in Cummings Research Park, with an option for an additional 15 acres for future expansion. The multi-year project carries a planned capital expenditure of more than $80 million and is expected to bring more than 150 full-time jobs to the region. Glaukos’ new facility is expected to be completed by 2030.